Literature DB >> 32461217

Secondary Hyperparathyroidism in a Patient with CKD.

Ryyan Hyder1, Stuart M Sprague2.   

Abstract

Entities:  

Keywords:  CKD; Chronic; Hyperparathyroidism; Renal Insufficiency; Secondary; parathyroid hormone

Year:  2020        PMID： 32461217      PMCID： PMC7341786          DOI： 10.2215/CJN.13411119

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  11 in total

1.  Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.

Authors:  Anna L Zisman; Marta Hristova; L Tammy Ho; Stuart M Sprague
Journal:  Am J Nephrol       Date:  2007-01-11       Impact factor: 3.754

Review 2.  Parathyroidectomy in the Management of Secondary Hyperparathyroidism.

Authors:  Wei Ling Lau; Yoshitsugu Obi; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-09       Impact factor: 8.237

Review 3.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

Review 4.  Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.

Authors:  John Cunningham; Francesco Locatelli; Mariano Rodriguez
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-31       Impact factor: 8.237

5.  Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.

Authors:  Jennifer L Ennis; Elaine M Worcester; Fredric L Coe; Stuart M Sprague
Journal:  J Nephrol       Date:  2015-03-04       Impact factor: 3.902

6.  Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

Authors:  Joachim H Ix; Tamara Isakova; Brett Larive; Kalani L Raphael; Dominic S Raj; Alfred K Cheung; Stuart M Sprague; Linda F Fried; Jennifer J Gassman; John P Middleton; Michael F Flessner; Geoffrey A Block; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2019-05-13       Impact factor: 10.121

Review 7.  Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.

Authors:  Stuart M Sprague; Daniel Coyne
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-04       Impact factor: 8.237

8.  A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.

Authors:  Daniel W Coyne; Seth Goldberg; Mark Faber; Cybele Ghossein; Stuart M Sprague
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-26       Impact factor: 8.237

9.  High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4: results of a 12-week double-blind, randomized, controlled study.

Authors:  Per-Anton Westerberg; Gunnar Sterner; Östen Ljunggren; Elin Isaksson; Fjölnir Elvarson; Hamid Dezfoolian; Torbjörn Linde
Journal:  Nephrol Dial Transplant       Date:  2018-03-01       Impact factor: 5.992

10.  Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion.

Authors:  Patricia P Centeno; Amanda Herberger; Hee-Chang Mun; Chialing Tu; Edward F Nemeth; Wenhan Chang; Arthur D Conigrave; Donald T Ward
Journal:  Nat Commun       Date:  2019-10-16       Impact factor: 14.919
View more
  1 in total

1.  Vascular Calcification in Chronic Kidney Disease: An Update and Perspective.

Authors:  Si-Chong Ren; Nan Mao; Si Yi; Xin Ma; Jia-Qiong Zou; Xiaoqiang Tang; Jun-Ming Fan
Journal:  Aging Dis       Date:  2022-06-01       Impact factor: 9.968
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.